Literature DB >> 17468153

Managing oral chemotherapy: the healthcare practitioner's role.

Carol S Viele1.   

Abstract

PURPOSE: [corrected] Management of the side effect profiles of the new oral cancer chemotherapeutic agents differs from those of traditional oral chemotherapy and hormonal therapy. The healthcare practitioner's role in counseling and managing these toxicities as well as methods for assessing and promoting adherence is reviewed.
SUMMARY: Many side effects from traditional oral cancer chemotherapeutic agents are the result of their effects on healthy cells as well as cancer cells. The side effects from the novel targeted therapies differ from those of traditional chemotherapy. Managing side effects and patient self-administration in non-traditional settings without supervision may affect patient adherence, especially with the newer agents. Social and psychological factors also can affect adherence. Various methods are available to assess adherence, including obtaining prescription refill histories and performing pill counts. Counseling patients, asking patients to keep a diary of doses and side effects, and following up with patients at clinic visits or through telephone contact are all methods that promote adherence. Patient education should address the proper dose, frequency, timing with respect to food and other medications, what to do if a dose is missed, side effects to anticipate, and what to do if side effects occur.
CONCLUSION: Healthcare practitioners play an important role in educating patients regarding potential side effects to oral chemotherapy and assessing and promoting adherence to the treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468153     DOI: 10.2146/ajhp070037

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  11 in total

1.  Pharmacists' role in targeted cancer therapy in Australia and implications for pharmacy education.

Authors:  David M Plevin; Helena M Ward; Michael B Ward; Michael J Sorich; Ross A McKinnon
Journal:  Am J Pharm Educ       Date:  2010-11-10       Impact factor: 2.047

2.  The α-lipoic acid derivative sodium zinc dihydrolipoylhistidinate reduces chemotherapy-induced alopecia in a rat model: a pilot study.

Authors:  Satoshi Hagiwara; Tomohisa Uchida; Hironori Koga; Masafumi Inomata; Fumitaka Yoshizumi; Masatsugu Moriyama; Seigo Kitano; Takayuki Noguchi
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

3.  Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel.

Authors:  Susan Goodin; Niesha Griffith; Beth Chen; Karen Chuk; Mikael Daouphars; Christian Doreau; Rinku A Patel; Rowena Schwartz; Maria José Tamés; Robert Terkola; Barbara Vadnais; Debbie Wright; Klaus Meier
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

4.  Development of the MASCC Teaching Tool for Patients Receiving Oral Agents for Cancer.

Authors:  Sultan Kav; Lisa Schulmeister; Anita Nirenberg; Linda Barber; Judi Johnson; Cynthia Rittenberg
Journal:  Support Care Cancer       Date:  2009-07-10       Impact factor: 3.603

5.  Unanticipated toxicities from anticancer therapies: survivors' perspectives.

Authors:  Mona Gandhi; Karen Oishi; Beth Zubal; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

Review 6.  Oral antineoplastic agents: how do we care about adherence?

Authors:  Marie Barillet; Virginie Prevost; Florence Joly; Bénédicte Clarisse
Journal:  Br J Clin Pharmacol       Date:  2015-10-28       Impact factor: 4.335

7.  Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.

Authors:  Lisa Hammond; Elaine Marsden; Niamh O'Hanlon; Fionnuala King; Martin Charles Henman; Claire Keane
Journal:  Int J Clin Pharm       Date:  2012-09-09

8.  Role of the nurse in patient education and follow-up of people receiving oral chemotherapy treatment: an international survey.

Authors:  Sultan Kav; Judi Johnson; Cynthia Rittenberg; Paz Fernadez-Ortega; Tarja Suominen; Pia Riis Olsen; Elisabeth Patiraki; Davina Porock; Annette Dahler; Jolanta Toliusiene; Dusanka Tadic; Pongpak Pittayapan; Vijay Roy; Qi Wang; Meric Colak; Hanan Saca-Hazboun; David Makumi; Ilana Kadmon; Sarah Ben Ami; Elsie Anderson; Rebecca Clark-Snow
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

9.  Putting the "Person" in Personalized Cancer Medicine: A Systematic Review of Psychological Aspects of Targeted Therapy.

Authors:  Daniel C McFarland; Jada G Hamilton; Rosanne Fox; Jimmie Holland
Journal:  Pers Med Oncol       Date:  2014-12

Review 10.  Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies.

Authors:  Gabriel Gazzé
Journal:  Melanoma Manag       Date:  2018-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.